Wake Forest Baptist Medical Center

Winston-Salem, North Carolina
Director, Cancer Genomics and Precision Oncology at Wake Forest Baptist Medical Center
Professor, Virginia Tech-Wake Forest University
Co-Director, ISB/MDACC Genome Data Analysis Center
President and Director, United States Chinese Anti-Cancer Association, Inc.


Dr. Zhang is a leader of precision oncology, using NFCR support since 2006 to characterize underlying genetic mechanisms responsible for cancer growth and progression. His research addresses the variability in cellular properties, within and across cancer types, which often leads to treatment resistance and poor survival in patients. For example, African-Americans diagnosed with lung cancer have higher incidences and lower survival rates than Caucasian Americans. Utilizing leading-edge genomic techniques, Dr. Zhang discovered that lung cancer in African-Americans expressed higher immunosuppressive components, permitting the lung cancer to escape attack by their immune system.

Dr. Zhang’s research has advanced our understanding of the role of genetic mutations in cancer progression and treatment: 1) lung cancer in African-Americans expresses a mutation in the TP53 tumor suppressor gene, leading to shorter survival times; 2) daily alcohol consumption causes DNA damage and changes in over 600 genes shown to be involved in cancer development; and 3) development of new computational methods utilizing artificial intelligence can predict the origin of cancers that have metastasized to the brain. Dr. Zhang’s precision oncology approach has the potential to improve outcomes for patients with non-Hodgkin’s lymphoma and leukemia, melanoma, and cancers of the lung, gastrointestinal tract, pancreas, ovary, uterus, brain and liver.


Wei Zhang, Ph.D., is the Director of Cancer Genomics and Precision Oncology at the Comprehensive Cancer Center of Wake Forest. He is also co-director of one of the Genome Data Analysis Centers.

Dr. Zhang graduated from Peking University in Beijing, China in 1985 before receiving his Ph.D. in molecular biology from the University of Texas. From 1999 to 2016, Dr. Zhang was the director of the Genomics Core Laboratory at MD Anderson’s Cancer Center. In 2004, he joined the faculty of MD Anderson’s Cancer Center and, in just two years, rose to the rank of full professor, teaching pathology and cancer biology. From 2014 to 2016, Dr. Zhang was the Director of the NFCR Center for Cancer System Informatics at MD Anderson’s Cancer Center.

Dr. Zhang has published more than 320 peer-reviewed papers and his research has been supported by numerous grants from the National Cancer Institute, the Department of Defense, the Texas Higher Education Coordinating Board and several foundations, including NFCR, the Goldhirsh Foundation, the James S. McDonald Foundation and the Shriver Initiatives for Sarcoma.

Related Content

5 Facts about Esophageal Cancer

Aside from the fact that it’s a tricky word to say, few people know much else about Esophageal Cancer—a relatively rare cancer. Esophageal cancer is cancer that impacts the 10-inch-long tube that connects the mouth to the stomach. That important track is vital to survive, and used daily, but esophageal cancer is shockingly referred to as a silent killer. Most people with esophageal cancer show no symptoms until after the cancer has spread. Understanding more about this disease can help people identify early warning signs both in themselves and in their loved ones. In recognition of Esophageal Cancer Awareness Month, the National Foundation for Cancer Research has compiled 5 lifesaving facts you need to know. Men are 3-4x more likely to develop esophageal cancer than women Men are far more likely to be diagnosed with esophageal cancer than women. Additionally, people between the ages of 45 and 70 have the highest risk of esophageal cancer. Though there are less than 20,000 cases in the United States each year, the survival rate is tragically low at 20%. Acid reflux, or esophageal reflux, may increase the risk of developing esophageal cancer According to a recent study, people with esophageal reflux disease, which also causes heartburn symptoms, have a higher risk of various cancers of the larynx (or voice box) and esophagus. Esophageal reflux disease, which affects approximately 20% of US adults, occurs when stomach acid flows back into the esophagus and causes tissue damage. The research team estimated that approximately 17% of larynx and esophageal cancers were linked to esophageal reflux disease. Esophageal spasms are not linked to cancer Esophageal spasms are abnormal muscle spasms in your esophagus. Depending on the severity of the esophageal spasm, they may cause pain and may disrupt the movement of food to the stomach. As uncomfortable as esophageal spasms can be, however, they are not actually connected to cancer. Though not linked to cancer, they can cause other health complications. Symptoms of esophageal spasms also imitate those of a heart attack and confusing the two can be life threatening. Those who experience esophageal spasms should contact their doctor to discuss how to safely distinguish between a spasm and a heart attack, as well as potential treatment options. Esophageal reflux can progress into a serious condition called Barrett’s Esophagus If someone suffers from esophageal reflux for an extended period of time, it may advance to a condition called Barrett’s Esophagus. This is caused by esophageal cells being saturated in stomach acid for a long time. The cells eventually begin to thicken as a defense mechanism to withstand the acid. Barrett’s Esophagus is considered a precancerous condition and increases esophageal cancer risk. While not all people with Barrett’s Esophagus will develop cancer, it is important to monitor the condition. A sponge may be the future of early esophageal cancer diagnosing The Cytosponge is a minimally invasive tool that allows doctors to collect and assess esophageal cells. The mechanism is a tiny, compressed sponge packed inside a clear pill that is swallowed by the patient under the doctor’s supervision. The sponge then releases and expands. The doctor pulls the […]

Research Highlight: Preventing Breast Cancer Brain Metastasis

National Foundation for Cancer Research funded researcher Dr. Daniel A Haber recently unearthed an exciting discovery that may add years to the lives of late-stage breast cancer patients. Dr. Haber is fascinated by understanding drug resistance on a deeper level by studying individual tumor cells in patients’ blood. In December 2020, Dr. Haber and his team shared their exciting findings on how brain metastasis, or the spread of cancer to the brain, may be prevented. Brain metastases occur in about 10% of all patients with cancer and in as many as a third of women with advanced metastatic breast cancer. Though experts have made great strides in suppressing the spread of cancer, there is still little known about the cellular pathways that enable cancer cells to selectively grow in the brain; that is, until Dr. Haber and his research team identified a signaling pathway which appeared significantly more active in brain metastases from breast cancer. “We were looking for what properties of some breast cancer cells made it possible for the cells to grow in the brain, which is a rare but often deadly complication of breast cancer,” Dr. Haber explained. “We weren’t sure what we would find. In a way that’s what makes the discovery process so exciting.” The research commenced approximately 10 years ago while investigating circulating tumor cells (CTCs). As their research progressed, the team homed in on a specific signaling pathway named HIF1A. Using cells from women with breast cancer, the team observed how these cells acted in animal models. It was discovered that if HIF1A was suppressed, the rate of proliferation (or rapid growth) was reduced. Simply put, blocking the HIF1A signaling pathway could reduce the rate of brain metastasis or even prevent it all together. “HIF1A is not specific to brain metastasis, since it’s a very broadly activated pathway in many cancers,” Dr. Haber began. “However, it appears to be more active in brain metastases from breast cancer than in primary breast cancers, and that may help explain what makes these metastases to the brain so unique and so difficult to treat.” The pathway identified in this research is already well known in the cancer world, however its special relevance to the brain was not known until now. Theoretically, a drug could be developed to suppress HIF1A and, in turn, prevent the spread of cancer. While a very promising discovery, Dr. Haber explains that there is far more work to be done. “There are a few HIF1A suppressing drugs now being tested in clinical trials for other indications,” Dr. Haber said, “However, we would have to expand this to multiple different models and systems before we could contemplate an intervention.” In regard to the length of time it takes to have a discovery such as this transitioned to mainstream treatment, Dr. Haber explains that it “depends on the discovery, its potential applications and some ‘luck’.” While the process from discovery to clinical treatment is getting faster all the time, it is likely going to take five to ten years before this finding is implemented into treatment. As for Dr. Haber, he has already planned plenty of work […]

FDA Recalls Popular Heartburn Drug Ranitidine: What You Need to Know

Medication commonly used to treat acid reflux and GERD pulled from the market after scientists find concerning levels of a potential cancer-causing substance in the drug. In April, the U.S. Food and Drug Administration (FDA) requested that all medications containing ranitidine be pulled from the market after an ongoing investigation uncovered concerning levels of a potential cancer-causing substance known as N-Nitrosodimethylamine (NDMA) in the drug.1 Also known by its brand name Zantac®, ranitidine is commonly used to treat individuals with acid reflux or gastroesophageal reflux disease (GERD). The recall included all prescription and over-the-counter (OTC) medications containing ranitidine. The National Foundation for Cancer Research (NFCR) understands that individuals who have taken or are currently taking ranitidine might have questions about this recall. Below, we answer some of the most frequently asked questions about this medication, the recall issued by the FDA, and how individuals can continue to manage their acid reflux or GERD. What is NDMA? NDMA is a common environmental contaminant found in water and certain foods. Although it does not cause any harm in small doses, NDMA may cause cancer in individuals who have been exposed to high doses over a long period of time.2 When did the FDA first identify NDMA in medications containing ranitidine? An independent laboratory first notified the FDA that NDMA had been found in medications containing ranitidine in 2019. This prompted the agency to conduct its own tests, which confirmed the presence of low levels of NDMA in ranitidine. However, there was not enough evidence to recommend whether individuals should continue or stop taking these medications. Recently, additional tests confirmed that the levels of NDMA in some medications containing ranitidine increase over time, particularly when the medicines are stored at higher than room temperature, resulting in individuals’ exposure to unacceptable levels of this potential cancer-causing substance. These new findings prompted the FDA to formally request that all medications containing ranitidine be pulled from the market in April 2020.1 What should I do if I have taken medications containing ranitidine in the past? If you or someone you know is currently taking a medication that contains ranitidine, the FDA recommends that you stop taking the medication, properly dispose of it, and not purchase more.1 Due to the ongoing COVID-19 pandemic, the FDA recommends that individuals dispose of their medications at home, instead of taking them to a drug take-back location.1 For information about how to safely dispose of medications containing ranitidine at home, individuals can review the disposal instructions in their medication package insert or follow the FDA’s recommended disposal steps. Does having acid reflux or GERD increase my risk for developing cancer? Having acid reflux or GERD is a known risk factor for developing certain cancers, including esophageal and stomach cancer. Although esophageal and stomach cancer are rare, these illnesses can be devastating for patients who are diagnosed. Oftentimes, neither illness causes symptoms in its early stages, with symptoms such as acid reflux or GERD appearing only after the disease has advanced. Visit the NFCR’s Stomach and Esophageal Cancers webpage for more information about both of these conditions. If you are concerned about […]